Nitrogen-containing heterocyclic compounds

Details Nitrogen-containing heterocyclic compounds Nitrogen-containing heterocyclic compounds

C - Chemistry, Metallurgy

07

D

C07D 239/94 (2006.01) A61K 31/495 (2006.01) A61K 31/496 (2006.01) A61K 31/502 (2006.01) A61K 31/517 (2006.01) A61K 31/53 (2006.01) A61K 31/535 (2006.01) A61K 31/54 (2006.01) A61K 31/55 (2006.01) C07D 215/46 (2006.01) C07D 217/22 (2006.01) C07D 237/28 (2006.01) C07D 237/34 (2006.01) C07D 401/12 (2006.01) C07D 403/12 (2006.01) C07D 405/12 (2006.01) C07D 409/12 (2006.01) C07D 413/12 (2006.01) C07D 417/12 (2006.01) C07D 471/04 (2006.01) C07D 487/04 (2006.01) C07D 491/056 (2006.01) C07D 498/04 (2006.01) C07D 513

Patent

CA 2239227

The present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of PDGF receptor to hinder abnormal cell growth and cell wandering and thus are useful for the prevention or treatment of cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis. The compounds are represented by general formula (I): (see Formula I) wherein V represents an oxygen atom or a sulfur atom; W represents 1,4-piperazinediyl or 1,4-homopiperazinediyl in which carbons on the ring may be substituted by unsubstituted alkyl groups; X represents a nitrogen atom or C-R9; Y represents a nitrogen atom or C-R8; Z represents a nitrogen atom or C-R7 (provided that at least one of X, Y and Z represents a nitrogen atom); R1 represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alicyclic alkyl group, etc.; R2 represents a substituted alkyl group, a substituted or unsubstituted alicyclic alkyl group, etc.; R3, R4, R5 and R6, which may be the same or different, each represents a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl group, a nitro group, a cyano group, - OR12, -NR15R16, etc.; R7 represents a halogen atom, etc.; R8 has the same significance as R7, and R9 represents a hydrogen atom or -COR41.

La présente invention concerne des composés azotés hétérocycliques représentés par la formule générale (I) et certains de leurs sels admis par la pharmacologie. Ces composés, qui empêchent la phosphorylation des accepteurs PDGF et la prolifération anormale ou la migration de cellules, conviennent particulièrement pour la prévention et le traitement des affection à prolifération cellulaire telles que l'artériosclérose, les affections réocclusives vasculaires, le cancer et la glomérulosclérose. "V" est oxygène ou soufre; "W" est 1,4-pipérazinediyl ou 1,4-homopipérazinediyl susceptible de substitution alkyl dans le cycle; "X" est azote ou C-R<9>; "Y" est azote ou C-R<8>; "Z" est azote ou C-R<7>, l'un au moins de X, Y et Z étant azote; "R<1>" est hydrogène, alkyle éventuellement substitué, cycloalkyle éventuellement substitué ou analogue; "R<2>" est alkyle substitué, cycloalkyle éventuellement substitué ou analogue; "R<3>", "R<4>", "R<5>" et "R<6>" sont chacun indépendamment hydrogène, halogéno, alkyl éventuellement substitué, nitro, cyano, -OR<12>, -NR<15>R<16> ou analogue; "R<7>" est halogéno ou analogue; "R<8>" est identique à ce qui a été antérieurement défini pour "R<7>"; et "R<9>" est hydrogène ou -COR<41>.

Affiliated with

Also associated with

Rating

Nitrogen-containing heterocyclic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nitrogen-containing heterocyclic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nitrogen-containing heterocyclic compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2014542